Abstract Many breast cancer survivors report a loss of sexual desire and arousability, consonant with the new DSM-V category of female sexual interest/arousal disorder. The cause of decreased sexual desire and pleasure after treatment for cancer is unknown. One possibility is that cancer, or treatment for cancer, damages brain circuits that are involved in rewardseeking. To test the hypothesis that brain reward systems are involved in decreased sexual desire in breast cancer survivors, we used functional magnetic resonance imaging (fMRI) to compare brain responses to erotica and other emotional stimuli in two groups of women previously treated for breast cancer with chemotherapy: those who were distressed about a perceived loss of sexual desire and those who may have had low desire, but were not distressed about it. Women distressed about their desire had reduced brain responses to erotica in the anterior cingulate and dorsolateral prefrontal cortex, which are part of the brain reward system. This study is the first to demonstrate, in cancer survivors, that problems with sexual desire/arousability are associated with blunted brain responses to erotica in reward systems. Future research is necessary to determine whether brain responses differ as a result of chemotherapy, hormone therapy, and menopausal status. This may contribute to the development of new, evidence-based interventions for one of the most prevalent and enduring side effects of cancer treatment.
After treatment for breast cancer, many women complain they have lost desire for sex and feel little pleasure with sexual stimulation. Some describe the change as feeling like a switch was flipped in their brain setting sex to "off." Low desire for sex is typically reported by 50 % to 80 % of women after breast cancer (Dizon 2009; Panjari et al. 2011) . Prevalence varies because most samples are relatively small and researchers use different measures of sexual dysfunction. In contrast, in a recent population-based study of healthy, postmenopausal women, only a third complained of low sexual desire (Trompeter et al. 2012) . It is clear that sexual dysfunction is more common in women treated with chemotherapy, regardless of initial menopausal status, and does not differ according to type of breast surgery, such as breast conservation versus mastectomy (Alder et al. 2008; Ganz et al. 1998; Schover et al. 1995) . In fact, in a prospective survey of 304 premenopausal women treated for ductal carcinoma in situ with breast surgery, and in some cases with radiation therapy or tamoxifen, but who did not have chemotherapy, sexual function and body image remained normal across 18 months of follow-up (Bober et al. 2013 ). Yet, a number of cohort studies also have found that sexual function is more likely to be disrupted if cancer treatment causes abrupt and continuing premature ovarian failure, whether the culprit is chemotherapy (Berglund et al. 2001; Burwell et al. 2006; Ochsenkühn et al. 2011; Panjari et al. 2011) , bilateral oophorectomy (Finch et al. 2011; Sayakhot et al. 2011) , or use of a gonadotropinreleasing hormone agonist (Berglund et al. 2001) .
The cause for loss of desire remains unclear. An early hypothesis was that a drop in circulating androgens in women in ovarian failure accounted for low desire, yet androgen levels in breast cancer survivors are not significantly correlated with self-reported sexual desire (Alder et al. 2008; Greendale et al. 2001; Speer et al. 2005) , nor was replacement testosterone effective in restoring desire in women with breast cancer in a randomized trial (Barton et al. 2007 ). Another hypothesis is that loss of desire for many women is a reaction to the painful experiences with sex that occur because of vulvovaginal atrophy (Burwell et al. 2006; Fobair et al. 2006; Schover 2008) , a sequence of dysfunctions that has also been observed in healthy, postmenopausal women (Avis et al. 2009 ). Since few trials are longitudinal, however, and the reaction to sexual pain can occur rapidly, it is difficult to ascertain whether pain is the cause of loss of desire. An often overlooked factor is that many breast cancer survivors use medications that blunt sexual desire to manage symptoms such as mood changes, hot flashes, pain, and fatigue (Dizon 2009; Suppli et al. 2011) .
A hypothesis that has not been explored is that chemotherapy directly damages brain circuits involved in sexual desire. Although controversy still exists about prevalence and severity of cognitive changes after chemotherapy for breast cancer, a number of studies have documented persistent deficits, especially in tasks involving working memory, executive functions, and attention (Collins et al. 2012; de Ruiter et al. 2012; Koppelmans et al. 2012; Wefel et al. 2004) . Affective processes, including those related to the expression of sexual desire, are functionally integrated with and supported by the same brain networks that support cognition (Lang and Bradley 2009; Lang et al. 1997; Pessoa 2008) . For example, in healthy participants, brain regions including the extended visual system (posterior parietal and occipital cortex) and the amygdala are activated both by tasks that demand attention and working memory and by the presentation of images that evoke an emotional response, whether pleasant or unpleasant (Lang et al. 1998; Morris et al. 1998; Pessoa et al. 2002; Sabatinelli et al. 2005) . Furthermore, pleasant stimuli (including erotic images) activate specific brain circuits associated with reward processing, such as the anterior cingulate, medial prefrontal cortex, and ventral striatum (Sabatinelli et al. 2007; Walter et al. 2008) . Brain imaging studies testing attention and executive functions in breast cancer survivors suggest that chemotherapy has a negative impact on the same brain regions (de Ruiter et al. 2011; Kesler et al. 2011) . Thus, cancer treatments affecting frontal cortical and subcortical networks could diminish the brain's ability to respond to stimuli that would normally trigger sexual desire.
One challenge is that sexual desire is difficult to define or measure. In recent years, a major controversy has been whether women's desire for sex can be separated from the subjective pleasure that occurs when physical and mental cues lead to sexual arousal. Many researchers believe that sexual desire and subjective sexual arousal are part of a single continuum but others continue to view them as separate entities (Bitzer et al. 2013) . DSM-V (American Psychiatric Association 2013) now groups desire and arousal together in defining Female Sexual Interest/Arousal Disorder. Another debate is whether most women experience a linear sequence of spontaneous desire leading to sexual arousal, or whether it is common for women to engage in sex because of social motivation, so that pleasant sexual sensations lead to desire for sex, which in turn amplifies erotic excitement in a circular fashion (Hayes 2011 ). Women's reports of sexual desire across varying situations do not support either DSM-IV (American Psychiatric Association 1994) or DSM-V diagnostic criteria for hypoactive desire disorder (Sarin et al. 2013 ). In particular, many women reporting a lack of interest in partner sex or masturbation acknowledge fairly frequent erotic thoughts and fantasies.
A model of sexual desire based closely on pharmacological and brain research with both animals and humans includes both excitatory and inhibitory components (Pfaus 2009 ). Excitation involves the hypothalamic and limbic systems. Steroid hormones prime the brain to respond to sexual cues. Premenopausal women report somewhat greater sexual desire at the time of ovulation, and functional magnetic resonance imaging (fMRI) of brain responses to sexual stimuli has confirmed a greater response during ovulation, although not in all studies (Stoleru et al. 2012) . Neurotransmitters, including dopamine, norepinephrine, melanocortin, and oxytocin, interact to stimulate sexual arousal and attention to sexual stimuli (Pfaus 2009 ). Areas particularly important to desire include the medial preoptic area (mPOA), the nucleus accumbens (NAcc), and the ventral tegmental area (VTA). As Holstege and Huynh (2011) point out, women's sexual arousal not only involves focusing on positive cues, but also on inhibiting areas of the brain that would normally be alert to nonsexual cues. Inhibitory mechanisms involve endogenous opioids, endocannabinoids, and serotonin.
Neuroimaging studies of women exposed to erotic stimuli are consistent with Pfaus' model (Stoleru et al. 2012 ). Brain areas showing activation in fMRI studies of women viewing erotic stimuli include the extended visual system, the insula, the orbitofrontal and medial prefrontal cortices, the anterior cingulate cortex, and the ventral striatum. Few brain imaging studies have compared women with normal versus low sexual desire. However, two recent studies found that women with low sexual desire show reduced activation in frontal and parietal areas relative to women with normal sexual desire (Arnow et al. 2009; Bianchi-Demicheli et al. 2011) . The goal of the present study was to collect preliminary data to evaluate whether breast cancer survivors distressed about loss of desire/arousability after chemotherapy show differences in brain activity from nondistressed women when viewing erotic and other emotional stimuli.
Methods
All study-related procedures were approved by the University of Texas MD Anderson Cancer Center's Institutional Review Board.
Participants
Forty-five eligible potential participants were identified and phone screened. Four women declined to participate due to lack of interest or difficulty with scheduling; eight cancelled or did not show up to their scheduled appointment. Four women that did not receive chemotherapy were not included in the analyses. Of the 29 women with a history of chemotherapy enrolled in the study, two were excluded due to excessive motion artifact in their fMRI data, resulting in a final sample size of 27 women. Women were eligible for the study if they were between 40 and 60 years of age, were at least 1 year post-menopause, had been previously diagnosed with Stage 0-III breast cancer or with noninvasive breast carcinoma, were currently free of known cancer, and were living within the greater Houston metropolitan area. Women were ineligible if they had any active cancer treatment in the previous 12 months, took any form of hormonal therapy or hormone replacement therapy in the previous 12 months, were using psychotropic medication, had a history of seizures or seizure disorder, had uncorrected vision impairments, had a current or past psychiatric or substance abuse disorder (except smoking), had any condition affecting their safety in the MRI (e.g., metal implants, claustrophobia), or could not communicate fluently in English. Participants were compensated $60 for their participation.
A list of potential participants was obtained from two databases at the University of Texas MD Anderson Cancer Center. Initial eligibility was assessed using information such as age, cancer stage, and recent treatment. A letter about the study was sent to potential participants with an opportunity to opt out of a follow-up phone call. Screening by phone was conducted by a female staff member. During the telephone interview, we collected basic demographic and health history information and assessed sexual desire using the Decreased Sexual Desire Screener (DSDS; Clayton et al. 2009 ), an instrument designed for use in studies of pharmacologic agents to treat low sexual desire in women. We used the first four questions from this questionnaire to classify participants. These items asked whether the participant 1) was satisfied with her level of sexual desire prior to her cancer diagnosis, 2) had noticed a decrease in her level of sexual desire since her cancer diagnosis, 3) was bothered by decreased sexual desire, and 4) would like her level of sexual desire to increase. We divided the participants in this study into two groups. The group distressed about low desire (DSDS-yes) consisted of 11 women who answered "yes" to all four questions on the DSDS. The nondistressed group (DSDS-no) consisted of 16 women who answered "no" to at least one of the questions. The most common negative answer in the nondistressed group (for 15 out of 16 participants) was to question #3 ("Are you bothered by your decreased level of sexual desire or interest?").
Stimuli
We measured brain responses to emotional stimuli using a picture-viewing procedure that has been previously used in our laboratory (Versace et al. 2011 ) and elsewhere (Bradley et al. 2003) . Sixty pictures were selected from the International Affective Picture System (Lang et al. 2008) . The pictures belonged to five categories, with 12 pictures each showing neutral people (NEU), erotic couples (ERO), romantic couples (ROM), mutilations (MUT), and sad scenes (SAD). Because some women with breast cancer may have negative emotions triggered by viewing erotic pictures of breasts, the ERO images did not include views of the whole breast that showed the nipples. The IAPS pictures used for each category were: NEU: 2102 NEU: , 2200 NEU: , 2210 NEU: , 2305 NEU: , 2383 NEU: , 2393 NEU: , 2396 NEU: , 2593 NEU: , 2595 NEU: , 2630 ERO: 4604, 4650, 4658, 4659, 4668, 4669, 4676, 4677, 4691, 4698; ROM: 4624, 4625, 4700; MUT: 3000, 3030, 3051, 3053, 3060, 3069, 3080, 3100, 3110, 3120, 3130, 3170; SAD: 2205 SAD: , 2455 SAD: , 2490 SAD: , 2590 SAD: , 2700 SAD: , 2703 SAD: , 2800 SAD: , 2900 Procedure Upon arrival at the laboratory, participants provided written, informed consent to participate. Then, using a computer, they completed several questionnaires: the Brief Symptom Inventory (a measure of anxiety an depressive symptoms; Derogatis 2001), the NEO-Five Factor Inventory (NEO-FFI; a measure of personality traits; McCrae and Costa 2004), the Sexual Arousal and Desire Inventory (SADI; Toledano and Pfaus 2006) , the Menopausal Sexual Interest Questionnaire (MSIQ; Rosen et al. 2004) , the Dyadic Adjustment Scale (DAS; Sabourin et al. 2005) , and the Female Sexual Function Index (FSFI; Wiegel et al. 2005) .
Following questionnaire assessment, participants entered the fMRI scanner and completed the picture-viewing procedure. The pictures were presented using an MR-compatible system (ESys/fMRI, Invivo, Gainesville, FL) running EPrime software (Psychology Software Tools, Pittsburgh, PA), such that they subtended a visual angle of 30°horizon-tally and 23°vertically. Before starting the picture presentation task, the participants were instructed to look at the pictures while the scanner measured their brain's reaction. To minimize the effect of picture presentation order on the results, each participant was randomly assigned to one of five picture presentation sequences. In all sequences, the pictures were presented in a random order with respect to category (NEU, ERO, ROM, MUT, and SAD) with the restriction that no more than 2 pictures of the same category were presented consecutively. Picture presentation was divided into two blocks of 30 pictures each, with a small break between the blocks. Each picture was presented for 5 s, followed by an intertrial interval ranging from 15 to 20 s. Each picture-viewing block lasted approximately 12 min.
During the picture presentation blocks, fMRI data were recorded using a 3.0 T Discovery MR750, 32-channel MRI system with high order shim (GE Healthcare, Milwaukee, WI). The blood-oxygenation-level-dependent (BOLD) signal was measured using a T2*-weighted, echo-planar, parallel imaging protocol with a 2.5 s repetition time, 25 ms echo time, and 90°flip angle. Parallel imaging used the Array Spatial Sensitivity Encoding Technique (ASSET) with an acceleration factor of 2. Data were collected as 58 contiguous 3-mm coronal slices with a 160 mm×160 mm field-of-view, 64×64 acquisition matrix, right-left phase encoding direction, and 2.5 mm×2.5 mm in-plane resolution. This resulted in full brain coverage with a spatial resolution of 2.5×2.5×3 mm. For each picture-viewing block, the first two volumes were discarded to allow magnetization to reach steady-state, followed by collection of 286 volumes that were time-locked to stimulus presentation. After the second picture-viewing block, a 3-dimensional, high-resolution, T1-weighted structural MRI was completed for purposes of mapping the BOLD data to brain anatomy (5.5 ms repetition time, 2.1 ms echo time, 400 ms inversion time, 20°flip angle, and 1 mm 3 voxel size). Following the MRI scan, participants used a computer to provide subjective ratings of the pictures used in the study. Affective valence (pleasure) and arousal ratings were collected using the Self-Assessment Manikin (SAM; Lang 1980), a visual-analog scale with 9 points. Then, participants were thanked for their participation, debriefed, compensated for their time, and dismissed.
Statistical analysis

Self-report measures
Questionnaire data were reported as means and standard errors for the entire sample and for the normal desire and low desire groups separately. Two-sample t -tests were used to compare scores between the two groups. The subjective ratings of the pictures (SAM ratings) were analyzed using group (nondistressed, versus distressed about low desire) × picture category (NEU, ERO, ROM, MUT, SAD) Analysis of Variance (ANOVA).
fMRI data fMRI data were analyzed using BrainVoyager QX, version 2.4 (Brain Innovation, Maastricht, The Netherlands; Goebel et al. 2006) . Following pre-processing, our analysis focused on identifying brain regions with 1) larger BOLD responses to emotional cues than neutral cues in all subjects and 2) differences in responses to emotional versus neutral stimuli between the nondistressed and distressed sexual desire groups.
For each subject and picture-viewing block, the raw fMRI data were preprocessed using the following steps: slice-timing correction using cubic spline interpolation, motion correction using a six-parameter rigid-body transformation with trilinear interpolation, spatial smoothing with a three-dimensional Gaussian spatial filter (5-mm full-width-at-half-maximum), and temporal filtering (high pass: 0.02 Hz). Two subjects who had estimated head motion parameters of >3 mm translation and/or >3°rota-tion in any direction were excluded from further analyses. The pre-processed images from each picture-viewing block were co-registered to the subject's anatomical MRI using a nine-parameter (translation, rotation, scale) gradient-based affine alignment, and transformed into standard stereotaxic (Talairach-Tournoux) space (3-mm isotropic voxels) through manual identification of reference points in the anatomical images.
For each subject, the Talairach-transformed fMRI images for both picture-viewing blocks were entered into a voxelwise general linear model (Mumford and Nichols 2009) . This model included a term for the predicted BOLD response for each picture category (NEU, ERO, ROM, MUT, SAD), obtained by convolving a boxcar function representing the stimulus timing with a canonical hemodynamic response function. Estimates of head motion parameters obtained during pre-processing and the overall mean signal level for each picture-viewing block were included in this model as nuisance parameters. All terms in the model were treated as fixed effects. Parameter estimates (β) were computed using ordinary least-squares estimation.
To identify brain regions with greater responses to emotional pictures than to neutral pictures, we used a mixed-effects general linear model. The β values for each subject and picture category were entered into this model. Each picture category was modeled as a fixed effect and subject was modeled as a random effect. A contrast of parameter estimates and its associated t-statistic was computed for the difference in response to neutral and emotional pictures (contrast coefficients of [−4, 1, 1, 1, 1] for [NEU, ERO, ROM, MUT, SAD], respectively). Clusters of voxels that exceeded a statistical threshold of t(26) > 3.07 (p <.005) and cluster-size threshold of 1,000 mm 3 were labeled as significantly active.
To identify brain regions where BOLD responses to emotional versus neutral stimuli differed between participants who were nondistressed or distressed about low sexual desire, the β values for each subject and picture category were entered into a 2×5 voxelwise ANOVA. In this ANOVA, group (distressed versus nondistressed) was a between subjects factor, and picture category (NEU, ERO, ROM, MUT, SAD) was a within-subjects factor. Thus, a significant group × picture category interaction reflects a difference in reactivity to at least one of the picture categories between subjects in the two groups. The F statistic for this interaction term was thresholded at F(4,100) > 3.96 (p <.005) with a minimum cluster size of 50 mm 3 . In each region that showed a significant group × picture category interaction, we conducted follow-up analyses to identify the specific picture categories that contributed to between-group differences. We conducted four ANOVAs with group (distressed versus nondistressed) as a between-subjects factor and picture category (NEU, emotional) as a withinsubjects factor. Each ANOVA tested one of the emotional picture categories (ERO, ROM, MUT, and SAD). Thus, a significant interaction in each follow-up test reflects a between-groups difference in activation to the specific category of emotional cue (relative to neutral cues).
Results
Self-report measures
Participant demographics and questionnaire scores are shown in Table 1 . The distressed and nondistressed groups (as defined by the DSDS screener) did not differ significantly on any questionnaire measure, including FSFI and MSIQ subscales measuring sexual desire (ps>.05). Responses suggested that both groups were below the norm in sexual desire, although the distressed group had somewhat poorer sexual function. The two groups also did not differ in their subjective ratings of valence and emotional arousal of the IAPS images used in the experiment (for Overall, BOLD responses were larger to emotional pictures than neutral pictures in the occipital lobes, posterior parietal lobes, inferior parietal lobule, anterior cingulate cortex, and dorsolateral prefrontal cortex (Table 2 ). In these regions, BOLD responses were largest in response to erotic pictures and smallest in response to neutral pictures (Fig. 1) .
To compare brain responses between participants distressed versus nondistressed about low sexual desire, we computed a group (nondistressed versus distressed) × picture category (NEU, ERO, ROM, MUT, SAD) voxelwise ANOVA. The group × picture category interaction was statistically significant in the anterior cingulate (Fig. 2) , dorsolateral prefrontal cortex, inferior occipital gyrus, superior temporal gyrus, and posterior insula (Table 3 ). These areas overlap with those that showed larger responses to emotional pictures than neutral pictures overall (Table 2) 
Discussion
Many breast cancer survivors report a loss of sexual desire and arousability. We hypothesized that this change may result from a chemotherapy-induced dysfunction in brain reward systems. Thus, our goal was to collect preliminary data about brain responses to erotic and other emotional stimuli in breast cancer survivors who were treated with chemotherapy. Breast cancer survivors with distressed about a loss of sexual desire had blunted responses to erotic and romantic pictures within brain reward circuits, including the anterior cingulate gyrus and dorsolateral prefrontal cortex. Although our findings are limited by the nature of our sample, they support the hypothesis that reduced sexual desire in breast cancer survivors could be the result of abnormal functioning in brain reward systems.
In healthy women with no cancer history, viewing of erotic stimuli results in increased activation in the anterior cingulate, medial prefrontal cortex, and nucleus accumbens (Sabatinelli et al. 2007; Stoleru et al. 2012; Walter et al. 2008) . Thus, these brain regions are thought to be involved in the desire for (or "wanting" of) sex, rather than the experience of pleasure during sex (Arnow et al. 2009; Bianchi-Demicheli et al. 2011; Georgiadis and Kringelbach 2012; Pfaus 2009 ). The nucleus accumbens, anterior cingulate, and medial prefrontal cortex all receive dopaminergic input from the ventral tegmental area. This neural network is thought to form a "seeking" system that motivates the pursuit of reward. In fact, this brain system is activated during anticipation of other forms of natural (e.g., food), conditioned (e.g., money), or pharmacological (e.g., drugs of abuse) rewards (Engelmann et al. 2012; Kuhn and Gallinat 2011; Sescousse et al. 2013) . Our finding that women who are dissatisfied with their desire for sex show decreased responses to erotica in the anterior cingulate is consistent with its involvement in sexual desire. Interestingly, we only found blunted brain responses to pleasant stimuli (i.e., erotic, and romantic images) and not to other categories of motivationally relevant stimuli, such as mutilations or sad pictures. Thus, the between groups difference in reaction to erotic cues cannot be attributed to a generalized difference in emotional reactivity, but appears to be specifically related to reward processing. These brain areas were identified from a whole-brain, voxelwise contrast of responses to emotional (Erotic, Romantic, Mutilation, and Sad) versus neutral pictures in all 27 participants. The statistical threshold for this analysis was a voxelwise p <.005 and a minimum cluster size of 1,000 mm 3 . Hem = Hemisphere; L = Left; R = Right; x, y, z = Talairach coordinates for the location of the center of gravity of the activation cluster, in mm; Size = volume of the activation cluster; t(26) max = Maximum t statistic observed in the activation cluster for the contrast between emotional and neutral pictures Due to the cross-sectional nature of our study, and the lack of a group of women treated for breast cancer who did not receive chemotherapy, we can only draw limited conclusions. The between-group differences observed here may be a consequence of cancer-related treatment or may have existed prior to cancer diagnosis or treatment. However, brain imaging studies of cognitive deficits in breast cancer survivors suggest that chemotherapy has a negative impact on frontal neural networks responsible for attention and executive functions (de Ruiter et al. 2011; Kesler et al. 2011) . Importantly, these are the same brain regions that are specifically activated by appetitive stimuli, including erotica (Sabatinelli et al. 2007 ). Thus, cancer treatments affecting frontal cortical and subcortical networks could diminish emotional processes, such as sexual desire. Future longitudinal studies including both pre-and post-treatment fMRI sessions are necessary to clarify the role of chemotherapy in altering brain responses to erotic cues and sexual desire.
Another challenge is separating the effects of chemotherapy, menopausal status, and self-reported sexual desire on reactivity to erotic stimuli. Although 7 participants in our study had been menopausal at breast cancer diagnosis (3 in the distressed and 4 in the nondistressed group), all were currently menopausal either because of cancer treatment or normal aging. A recent comparison of premenopausal women on versus off oral contraceptives suggested that serum estradiol does not change women's fMRI responses to intense erotic videos or photos, but decreased levels did attenuate brain responses when women were given the expectation that the next image would be erotic (Abler et al. 2013) . Future studies, ideally using a prospective design, should compare BOLD responses to erotic images in women who maintain menstrual cycles after chemotherapy with an age-matched group in premature ovarian failure. Another important comparison is with women who do not have chemotherapy or hormonal therapy as part of the treatment for breast cancer. It is difficult to find such women, given that even those with early stage disease typically have adjuvant systemic therapies. However, women with ductal carcinoma in situ (DCIS) sometimes have only local therapy, and could be a comparison group for future studies. Our limited funding did The time course of activation was expressed as the percent change from the region's mean level of activation across the entire session. For each trial, the time course was baseline-corrected by subtracting the mean signal measured from 2.5 s before through 2.5 s after picture onset from each volume (Versace et al. 2011) . Trials were then averaged across picture categories and participants and plotted above not allow us to include a DCIS group in this pilot study. A recent survey of sexually active survivors of treatment for DCIS found normal levels of sexual function and body image, even though almost half were postmenopausal (Bober et al. 2013) . Premenopausal women whose breast cancer treatment does not cause premature ovarian failure also report better sexual function than those who become menopausal (Ochsenkühn et al. 2011) .
Another limitation of this study is that women who were dissatisfied with their desire according to the DSDS (Clayton et al. 2009 ) may not have met all diagnostic criteria for female Sexual Interest/Arousal Disorder (American Psychiatric Association 2000), but still were distressed about their perceived loss of desire since breast cancer treatment. In addition, the two groups did not differ significantly on total scores or desire subscale scores on two questionnaires designed to assess female sexual desire, the FSFI and MSIQ. In fact, scores for women in the nondistressed group would indicate abnormally poor sexual function according to the norms for these tests (Rosen et al. 2004; Wiegel et al. 2005 ). This suggests that blunted brain responses to erotica might only be present in the most extreme cases of sexual dysfunction, such as in women who not only report low desire/arousability, but are also distressed about the problem. Since societal norms about female sexuality are often contradictory and confusing, distress has been considered as central to a diagnosis of low desire in women since DSM-IV-TR, and is reported by over 80 % of women who met DSM-IV-TR criteria for a desire disorder (Derogatis et al. 2008) . Distress may be even more important when a medical illness and treatment cause physiological damage to a woman's ability to enjoy sex. Future research should address the quantitative relationship between sexual dysfunction measured using a variety of scales and brain responses to erotic cues.
Notwithstanding these limitations, our results provide initial evidence that breast cancer survivors with very low sexual desire have blunted brain responses in frontal regions while viewing erotic and romantic images. Dysfunctions in the brain reward systems may contribute to the high incidence of sexual dysfunction in breast cancer survivors. Efforts to find a drug that would increase women's desire for sex have thus far been largely unsuccessful (Bradford 2013) . Further study of the mechanisms that reduce sexual desire and arousability in breast cancer survivors may foster the development of new, evidencebased interventions for one of the most prevalent and enduring side effects of cancer treatment. These brain areas were identified from a whole-brain, voxelwise Analysis of Variance (ANOVA) with distressed versus nondistressed about low sexual desire as a between-subjects factor and Picture Category (Neutral, Erotic, Romantic, Mutilation, and Sad) as a within-subjects factor. The statistical threshold for this analysis was a voxelwise p <.005 and a minimum cluster size of 50 mm 3 . Hem = Hemisphere; L = Left; R = Right; x, y, z = Talairach coordinates for the location of the center of gravity of the activation cluster, in mm; Size = volume of the activation cluster; F(4, 100) max = Maximum F statistic observed in the activation cluster for the Sexual Dysfunction × Picture Category interaction
